Combining factor VIII levels and thrombin/plasmin generation: A population pharmacokinetic‐pharmacodynamic model for patients with haemophilia A. Issue 6 (15th January 2022)

• Record Type: Journal Article
• Authors: Bukkems, Laura H.; Valke, Lars L. F. G.; Barteling, Wideke; Laros‐van Gorkom, Britta A. P.; Blijlevens, Nicole M. A.; Cnossen, Marjon H.; van Heerde, Waander L.; Schols, Saskia E. M.; Mathôt, Ron A. A.
• Other Names: Mifsud Janet guestEditor.; Cranswick Noel guestEditor.
• Is Part Of: British journal of clinical pharmacology. Volume 88:Issue 6(2022)
• Page Start: 2757
• Page End: 2768
• Publication Date: 2022-01-15
• Subjects: factor VIII -- haemophilia A -- pharmacodynamics -- pharmacokinetics -- plasmin generation -- thrombin generation -- treatment individualization; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.15185
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: Prophylactic treatment of haemophilia A patients with factor VIII (FVIII) concentrate focuses on maintaining a minimal trough FVIII activity level to prevent bleeding. However, due to differences in bleeding tendency, the pharmacokinetic (PK)‐guided dosing approach may be suboptimal. An alternative approach could be the addition of haemostatic pharmacodynamic (PD) parameters, reflecting a patient's unique haemostatic balance. Our aim was to develop a population PK/PD model, based on FVIII activity levels and Nijmegen Haemostasis Assay (NHA) patterns, a global haemostatic assay that measures thrombin/plasmin generation simultaneously. Methods: PK/PD measurements were collected from 30 patients treated with standard half‐life FVIII concentrate. The relationship between FVIII activity levels and the thrombin/plasmin generation parameters (thrombin potential, thrombin peak height and plasmin peak height), were described by sigmoidal E max functions. Results: The obtained EC50 value was smallest for the normalized thrombin potential (11.6 IU/dL), followed by normalized thrombin peak height (56.6 IU/dL) and normalized plasmin peak height (593 IU/dL), demonstrating that normalized thrombin potential showed 50% of the maximal effect at lower FVIII activity levels. Substantial inter‐individual variability in the PD parameters, such as EC50 of thrombin potential (86.9%) was observed, indicating that, despite similar FVIII activity levels, haemostatic capacity varies significantly between patients. Conclusion: These data suggest that dosing based on patients' individual PK/PD parameters may be beneficial over dosing solely on individual PK parameters. This model could be used as proof‐of‐principle to examine the application of PK/PD‐guided dosing. However, the relation between the PD parameters and bleeding has to be better defined.